I. Rooney

发表

Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans

E. Choo, C. Hop, J. Halladay, 2016, Drug Metabolism and Disposition.

Association of programmed death ligand‐1 (PD‐L1) expression with treatment outcomes in patients with BRAF mutation‐positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib

P. Ascierto, J. Larkin, A. Ribas, 2018, Pigment cell & melanoma research.

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

E. Winer, K. Morrissey, J. Spoerke, 2018, Breast Cancer Research.

Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects.

E. Choo, L. Musib, S. Eppler, 2013, Molecular pharmaceutics.

25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study

P. Ascierto, J. Larkin, A. Ribas, 2015 .

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.

R. Laing, S. Chan, L. Fehrenbacher, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

621 A Phase I Dose-escalation Study of MFGR1877S, a Human Monoclonal Anti-fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients (pts) with Advanced Solid Tumors

E. Lam, YounJeong Choi, J. Goldman, 2012 .

P. Ascierto, J. Larkin, A. Ribas, 2018, British Journal of Cancer.

Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial

K. Flaherty, A. Arance, H. Gogas, 2019, Annals of Oncology.

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma

A. Ribas, I. Puzanov, A. Daud, 2019, Clinical Cancer Research.

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.

Matthew Wongchenko, Paolo A Ascierto, Antoni Ribas, 2016, The Lancet. Oncology.

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma

P. Ascierto, J. Larkin, J. Sosman, 2019, Clinical Cancer Research.

Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase 3 IMspire170 study.

K. Flaherty, J. Larkin, H. Gogas, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

E. Winer, K. Morrissey, J. Spoerke, 2018, Breast Cancer Research.

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

Matthew Wongchenko, Jeffrey E Gershenwald, Lauren E Haydu, 2018, The Lancet. Oncology.

MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer

A. Ashkenazi, Xiangnan Du, J. Qing, 2014, Clinical Cancer Research.

Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET

H. Burris, J. Infante, L. Rosen, 2013, Investigational New Drugs.

Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study

A. Hauschild, P. Ascierto, J. Larkin, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

results from a randomised, double-blind, phase 3 trial

P. Ascierto, J. Larkin, A. Ribas, 2016 .

Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study.

P. Ascierto, J. Larkin, A. Ribas, 2018 .

Melanoma and immunotherapy bridge 2015

Andrew J. Park, Ludmila V. Danilova, David C. Smith, 2016, Journal of Translational Medicine.

Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma.

P. Ascierto, J. Larkin, A. Ribas, 2015 .

Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib

P. Hegde, P. Ascierto, J. Larkin, 2017, Clinical Cancer Research.

Abstract P5-19-10: Tolerability and anti-tumor activity of the oral PI3K inhibitor GDC-0941 in combination with paclitaxel, with and without bevacizumab or trastuzumab in patients with locally recurrent or metastatic breast cancer

E. Winer, K. Morrissey, J. Spoerke, 2015 .

Abstract B75: A first in-human phase I study to evaluate the MEK1/2 inhibitor GDC-0623 in patients with advanced solid tumors.

A. El-Khoueiry, J. Bendell, I. Chang, 2013 .

Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity.

K. Flaherty, W. Miller, Carrie Lee, 2017 .

Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study.

P. Ascierto, J. Larkin, A. Ribas, 2018, JCO precision oncology.

Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone

P. Ascierto, J. Larkin, J. Sosman, 2016 .

Clinical predictors of response for coBRIM: A phase III study of cobimetinib (C) in combination with vemurafenib (V) in advanced BRAF-mutated melanoma (MM).

P. Ascierto, J. Larkin, A. Ribas, 2016 .

Efficacy of cobimetinib (C) and vemurafenib (V) in advanced BRAF-mutated melanoma patients (pts) with poor and favorable prognosis in the coBRIM phase III study.

P. Ascierto, J. Larkin, A. Ribas, 2016 .

Adverse event (AE) incidence rates with cobimetinib (C) plus vemurafenib (V) treatment: Extended follow-up (f/u) of the phase III coBRIM study.

P. Ascierto, J. Larkin, A. Ribas, 2016 .